Cory Perla

In this Healio video, Robert C. Stowe, MD, an instructor of neurology at Boston Children’s Hospital and Harvard Medical School, discusses a new perspective on how sleep and circadian rhythms influence seizures.The inherent driving mechanisms that encourage sleep may be a part of the “seizure propagation network,” Stowe said.

Robert C. Stowe, MD, an instructor of neurology at Boston Children’s Hospital and Harvard Medical School, discusses key features from his session at the Child Neurology Society annual meeting in this Healio video.The session “highlighted the challenges that exist in the clinical entity of developmental and epileptic encephalopathy with spike-wave activation in sleep,”

In this expert perspective from Hawaiian Eye 2024, Sunir J. Garg, MD, FACS, FASRS, discusses aflibercept 8 mg as a possible treatment for retinal vein occlusion.“One of the things I’m most looking forward to for the treatment of retinal vein occlusion in 2024 is the use of aflibercept 8 mg to treat patients with this disease,” Garg, professor of ophthalmology at the retina

In this video, Laleh Melstrom, MD, MS, discusses results from the NABNEC study, a randomized phase 2 study of nab-paclitaxel in combination with carboplatin as first-line treatment of gastrointestinal neuroendocrine carcinomas.The experimental arm had higher response rates than the control arm, Melstrom, a surgical oncologist at City of Hope, said of the study presented at ASCO Gastrointestinal

In this video, Afsaneh Barzi, MD, PhD, discussed research that examined the risks when using a watch-and-wait approach for rectal cancer. The study, presented at ASCO Gastrointestinal Cancers Symposium showed that for patients who experienced local regrowth of their rectal cancer, the likelihood of distant recurrent disease was significantly higher.

In this video, Afsaneh Barzi, MD, PhD, discussed the phase 2 results from the NRG-GI005 (COBRA) study.The study, presented at ASCO Gastrointestinal Cancers Symposium, examined the role of circulating tumor DNA (ctDNA) in directing adjuvant chemotherapy for patients with stage II colon cancer.

SEATTLE — In this video, Eleonora M. Lad, MD, PhD, vice chair of ophthalmology clinical research at Duke Health, discusses highlights in age-related macular degeneration from the ARVO meeting.

SEATTLE — In this video, Eleonora M. Lad, MD, PhD, vice chair of ophthalmology clinical research at Duke Health, discusses an update on the use of anti-VEGF biosimilars for the treatment of age-related macular degeneration.

SEATTLE — In this video, Eleonora M. Lad, MD, PhD, vice chair of ophthalmology clinical research at Duke Health, discusses a presentation at the ARVO annual meeting on patient preferences for retinal prosthesis options.

Pegcetacoplan may be a more effective treatment option than avacincaptad pegol for reducing geographic atrophy lesion growth in patients with age-related macular degeneration.The study, presented at the American Society of Retina Specialists annual meeting by Paul Hahn, MD, PhD, FASRS, a retina specialist at NJRetina, compared intravitreal pegcetacoplan (PEG) vs. avacincaptad pegol (ACP) for the

In this video, Barbara Blodi, MD, discusses advancements in gene therapy for the treatment of age-related macular degeneration.At the ASRS annual meeting, several sessions revolved around gene therapy in clinical trials from various companies and delivery of the therapy.

In this video, Barbara Blodi, MD, discusses advancements in complement inhibition treatments for geographic atrophy.At the ASRS annual meeting, there were panel discussions about the pros and cons of these types of therapies, Blodi said.

CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses highlights from the AAO meeting.

CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses controversies surrounding the use of complement inhibitors for the treatment of geographic atrophy.

CHICAGO — In this video, Joan W. Miller, MD, chair of ophthalmology at Mass Eye and Ear, discusses study results presented at the AAO meeting on ONL1204 from ONL Therapeutics.“It’s a very different approach, really more of a neuroprotective approach for [geographic atrophy] and that I think is kind of exciting,” Miller said.

CHICAGO — In this video, Karl G. Csaky, MD, PhD, discusses highlights from the AAO annual meeting.In a panel discussion on dry age-related macular degeneration, experts debated the importance of anatomic vs. functional benefits of dry AMD therapies, according to Csaky, chief executive and medical officer of the Retina Foundation of the Southwest in Dallas.

CHICAGO —In this video, Karl G. Csaky, MD, PhD, highlights discussions from the AAO meeting on the adequacy of tools used to assess the effectiveness of treatments for dry age-related macular degeneration.

CHICAGO — In this video, Clement K. Chan, MD, FACS, discusses highlights from the AAO meeting, including presentations on pegcetacoplan and avacincaptad pegol for the treatment of geographic atrophy.In addition, Chan, a retina specialist at Desert Retina Consultants, recaps a panel discussion during which experts shared their opinions on the use of these therapies for the treatment of GA.

SAN DIEGO —In this video, Jennifer A. Woyach, MD, discusses results from the AMPLIFY trial, presented at ASH Annual Meeting and Exhibition.The trial evaluated fixed-duration acalabrutinib (Calquence, AstraZeneca) plus venetoclax (Venclexta, AbbVie) with or without obinutuzumab (Gazyva, Genentech) versus chemoimmunotherapy as front-line treatment for chronic lymphocytic leukemia.

SAN DIEGO —In this video, Jennifer A. Woyach, MD, discusses two abstracts from ASH Annual Meeting and Exhibition that evaluated the use of immune therapies to treat chronic lymphocytic leukemia.